RBC Capital Reiterates Outperform on ADC Therapeutics, Maintains $8 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Gregory Renza has reiterated an Outperform rating on ADC Therapeutics (NYSE:ADCT) and maintained a price target of $8.
August 07, 2024 | 3:32 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital analyst Gregory Renza has reiterated an Outperform rating on ADC Therapeutics and maintained a price target of $8.
The reiteration of an Outperform rating and the maintenance of a price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100